A class-action lawsuit was filed Tuesday against UnitedHealth Group and a subsidiary alleging that they are illegally using an algorithm to deny rehabilitation care to
The JAMA study finds individual blood pressure responses to dietary sodium variations are consistent across different subgroups, including those on antihypertensive medications, suggesting a universal
Study predicts that a vaccine against group A Streptococcus (Strep A) could significantly reduce antibiotic prescriptions for sore throat, potentially leading to a 33% decrease
Study reveals that coffee consumption is associated with a reduced risk of developing irritable bowel syndrome (IBS), as determined by a systematic review and meta-analysis
The study in Scientific Reports finds no significant association between cannabis use and the risk of primary open-angle glaucoma, challenging the notion that cannabis could
Study demonstrates the use of cellulose nanofiber sheets for spatial analysis of extracellular vesicles, revealing their geographical heterogeneity in the human body, which could advance
The wonders of psychedelics—the what-ifs, the how-tos, the why-nots—were on hand on three main stages at Miami’s Ice Palace Film Studios at the 2023 Wonderland
In Stockton, California, almost 60% of the city’s 320,000 residents are prediabetic or living with diabetes. Shane Bailey, a 72-year-old longtime resident and U.S. Coast
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment
Share this article Orphelia has developed Kizfizo as the first oral suspension of temozolomide to treat neuroblastoma. Credit: Nyaaka/Shutterstock.com Orphelia Pharma is taking action to